Loading clinical trials...
Loading clinical trials...
This study is a multi-center, double-blind, placebo-controlled, randomized Phase 3 trial to assess the safety and efficacy of AXS-12 in narcoleptic subjects with cataplexy and excessive daytime sleepi...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Axsome Therapeutics, Inc.
NCT05939453 · Prader-Willi Syndrome, Excessive Daytime Sleepiness, and more
NCT07299097 · Narcolepsy Type 1, Narcolepsy Type 2
NCT07363720 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
NCT05816382 · Narcolepsy Type 1
NCT06767683 · Narcolepsy Type 1, Narcolepsy Type 2, and more
Clinical Research Site
Alabaster, Alabama
Clinical Research Site
Peoria, Arizona
Clinical Research Site
Phoenix, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions